PegBio is a Chinese innovative drug developer.
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 15, 2015 | Series C | ¥7M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Mingxin China Growth Fund | — | Series C |